Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: the TropNet Severe Malaria Study

Florian Kurth, Michel Develoux, Matthieu Mechain, Jan Clerinx, Spinello Antinori, Ida E Gjørup, Joaquím Gascon, Kristine Mørch, Emanuele Nicastri, Michael Ramharter, Alessandro Bartoloni, Leo Visser, Thierry Rolling, Philipp Zanger, Guido Calleri, Joaquín Salas-Coronas, Henrik Ib Nielsen, Gudrun Just-Nübling, Andreas Neumayr, Anna HachfeldMatthias L Schmid, Pietro Antonini, Peter Pongratz, Peter Kern, José Saraiva da Cunha, Antoni Soriano-Arandes, Mirjam Schunk, Norbert Suttorp, Christoph Hatz, Thomas Zoller, Tropnet Severe Malaria Investigator Group

Research output: Contribution to journalJournal articleResearchpeer-review

38 Citations (Scopus)

Abstract

Intravenous artesunate improves survival in severe malaria, but clinical trial data from non-endemic countries are scarce. The TropNet severe malaria database was analyzed to compare outcomes of artesunate vs. quinine treatment. Artesunate reduced parasite clearance time, duration of ICU- and hospital treatment in European patients with imported severe malaria.

Original languageEnglish
JournalClinical Infectious Diseases
Volume61
Issue number9
Pages (from-to)1441-1444
Number of pages4
ISSN1058-4838
DOIs
Publication statusPublished - 2015

Fingerprint

Dive into the research topics of 'Intravenous artesunate reduces parasite clearance time, duration of intensive care, and hospital treatment in patients with severe malaria in Europe: the TropNet Severe Malaria Study'. Together they form a unique fingerprint.

Cite this